News

Phase 2 Clinical Trial Results of Telacebec Published in NEJM

On March 25th, Qurient announced the results of their Phase 2 Clinical Trial  (ClinicalTrials.gov number, NCT03563599), which was a prospective, randomized, open-label trial for proof of concept in humans of their novel anti-tuberculosis drug, Telacebec (Q203). The trial involved 61 newly-diagnosed patients with drug-susceptible pulmonary tuberculosis. Patients received a dose of 100 mg, 200 mg, or 300 mg once daily or combination therapy with rifampin, isoniazid, pyrazinamide, and ethambutol (RHZE) as reported in the New England Journal of Medicine. According to the article, increasing doses of telacebec were associated with greater reductions in time to positivity of collected sputum samples, which they used to determine bactericidal activity. 

To read more about this latest trial by Qurient, take a look at their press release on Business Wire or their article published in the New England Journal of Medicine

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...